Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2021 | 12-2020 | 12-2019 | 12-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -94,659 | -80,902 | -88,275 | -53,335 | -42,015 |
| Depreciation Amortization | 305 | 238 | 83 | 111 | 258 |
| Accounts payable and accrued liabilities | -109 | 1,194 | -277 | -48 | -1,217 |
| Other Working Capital | 2,539 | 795 | -1,975 | 1,381 | -342 |
| Other Operating Activity | 12,960 | 26,308 | 39,261 | 6,776 | 7,153 |
| Operating Cash Flow | $-78,964 | $-52,367 | $-51,183 | $-45,115 | $-36,163 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -72 | -12 | -39 | -118 | -92 |
| Investing Cash Flow | $-72 | $-12 | $-39 | $-118 | $-92 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 4,955 | N/A |
| Debt Repayment | N/A | N/A | -5,438 | N/A | N/A |
| Common Stock Issued | 79,808 | 8,901 | 98,176 | 46,176 | 27,588 |
| Financing Cash Flow | $79,808 | $8,901 | $92,738 | $51,131 | $27,588 |
| Exchange Rate Effect | -78 | 5 | -34 | -88 | -4 |
| Beginning Cash Position | 104,355 | 147,828 | 106,346 | 100,536 | 109,207 |
| End Cash Position | 105,049 | 104,355 | 147,828 | 106,346 | 100,536 |
| Net Cash Flow | $694 | $-43,473 | $41,482 | $5,810 | $-8,671 |
| Free Cash Flow | |||||
| Operating Cash Flow | -78,964 | -52,367 | -51,183 | -45,115 | -36,163 |
| Capital Expenditure | -72 | -12 | -39 | -118 | -92 |
| Free Cash Flow | -79,036 | -52,379 | -51,222 | -45,233 | -36,255 |